<DOC>
	<DOCNO>NCT02553499</DOCNO>
	<brief_summary>In study , participant advance solid tumor assign receive either MK-1248 alone combination pembrolizumab ( MK-3475 ) . This study use adaptive design find confirm maximum tolerate dose ( MTD , maximum administer dose [ MAD ] ) MK-1248 alone combination pembrolizumab .</brief_summary>
	<brief_title>Study MK-1248 With Without Pembrolizumab ( MK-3475 ) Participants With Advanced Solid Tumors ( MK-1248-001 )</brief_title>
	<detailed_description />
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically cytologicallyconfirmed metastatic solid tumor available therapy may convey clinical benefit Measurable disease Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 criterion . Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale Adequate organ function Female participant childbearing potential willing use adequate contraception course study 120 day last dose study medication Male participant agree use adequate contraception start first dose study therapy 180 day last dose study medication Can submit baseline tumor sample Has chemotherapy , radiation , biological cancer therapy within 4 week prior first dose study medication , recover adverse event due cancer therapeutic administer 4 week earlier Currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose study medication Previous treatment another agent target glucocorticoidinduced tumor necrosis factor receptorrelated protein ( GITR ) receptor Previous treatment immunomodulatory therapy discontinue therapy due immunerelated adverse event Expected require form antineoplastic therapy study On chronic systemic steroid therapy excess replacement dos , form immunosuppressive medication History previous , additional malignancy , unless potentially curative treatment complete , evidence malignancy 5 year exception successful definitive resection basal cell carcinoma skin , superficial bladder cancer situ cervical cancer Known active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Severe hypersensitivity reaction treatment another monoclonal antibody Active autoimmune disease document history autoimmune disease exception vitiligo resolve childhood asthma/atopy , endocrine deficiency follow treatment immunomodulatory agent Active infection require therapy Active history noninfectious pneumonitis Prior stem cell bone marrow transplant Known history Human Immunodeficiency Virus ( HIV ) , active chronic acute Hepatitis B C Known psychiatric substance abuse disorder would interfere cooperation requirement study Regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) substance abuse ( include alcohol ) , time signing informed consent Symptomatic ascites pleural effusion Pregnant , breastfeeding , expect conceive father child within project duration study 180 day last dose study medication Major surgery within 16 week prior screen Live vaccine within 30 day prior first dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid tumor</keyword>
	<keyword>PD1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>PDL1</keyword>
</DOC>